Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
52.97 (1y: +19%)
Market Cap 142.12 B P/E(ttm) 20.60
Enterprise Value 165.46 B P/B 16.32
GSK- NYSE (USA)
GlaxoSmithKline PLC
  • Currently 2/5
Business Predictability Rank: 2-Star (On Watch)
Back Testing Results:
Average gain of all 2-Star stocks: 6% per year.
% of Stocks that are in still loss if held for 10yrs: 16%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$52.97
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.233
GSK's Cash to Debt is ranked lower than
91% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.28 vs. GSK: 0.233 )
GSK' s 10-Year Cash to Debt Range
Min: 0.23   Max: 0.85
Current: 0.23
0.23
0.85
Equity to Asset -0.21
GSK's Equity to Asset is ranked lower than
96% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.56 vs. GSK: -0.21 )
GSK' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.31
Current: -0.21
-0.21
0.31
Interest Coverage 10.1
GSK's Interest Coverage is ranked lower than
57% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.90 vs. GSK: 10.1 )
GSK' s 10-Year Interest Coverage Range
Min: 2   Max: 251
Current: 10.1
2
251
F-Score: 5
Z-Score: 2.69
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 28.00
GSK's Operating margin (%) is ranked higher than
91% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.80 vs. GSK: 28.00 )
GSK' s 10-Year Operating margin (%) Range
Min: 1.7   Max: 34.9
Current: 28
1.7
34.9
Net-margin (%) 17.3
GSK's Net-margin (%) is ranked higher than
82% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. GSK: 17.3 )
GSK' s 10-Year Net-margin (%) Range
Min: 5.8   Max: 23.3
Current: 17.3
5.8
23.3
ROE (%) 78.6
GSK's ROE (%) is ranked higher than
99% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. GSK: 78.6 )
GSK' s 10-Year ROE (%) Range
Min: 18.4   Max: 78.6
Current: 78.6
18.4
78.6
ROA (%) 11
GSK's ROA (%) is ranked higher than
87% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. GSK: 11 )
GSK' s 10-Year ROA (%) Range
Min: 3.9   Max: 21.1
Current: 11
3.9
21.1
ROC (Joel Greenblatt) (%) 92.20
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.40 vs. GSK: 92.20 )
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.1   Max: 116.4
Current: 92.2
5.1
116.4
Revenue Growth (%) -1.1
GSK's Revenue Growth (%) is ranked lower than
81% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. GSK: -1.1 )
GSK' s 10-Year Revenue Growth (%) Range
Min: -1.1   Max: 11.3
Current: -1.1
-1.1
11.3
EBITDA Growth (%) -2.5
GSK's EBITDA Growth (%) is ranked lower than
76% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GSK: -2.5 )
GSK' s 10-Year EBITDA Growth (%) Range
Min: -32.8   Max: 64.2
Current: -2.5
-32.8
64.2
EPS Growth (%) -4.1
GSK's EPS Growth (%) is ranked lower than
78% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GSK: -4.1 )
GSK' s 10-Year EPS Growth (%) Range
Min: -23.7   Max: 10.6
Current: -4.1
-23.7
10.6
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

GSK Guru Trades in Q2 2012

Jim Simons 1,651,000 sh (+117.15%)
Manning & Napier Advisors, Inc 308,560 sh (+91.51%)
Steven Cohen 144,154 sh (+55.9%)
John Hussman 19,500 sh (+18.18%)
Jean-Marie Eveillard 341,601 sh (+5.86%)
Murray Stahl 23,673 sh (unchged)
Vanguard Health Care Fund 2,742,381 sh (unchged)
Warren Buffett 1,510,500 sh (unchged)
Tweedy Browne 135,141 sh (-0.38%)
Jeff Auxier 71,845 sh (-0.48%)
Ken Fisher 11,275,330 sh (-1.19%)
NWQ Managers 170,500 sh (-1.39%)
Dodge & Cox 58,961,974 sh (-3.64%)
PRIMECAP Management 11,533,268 sh (-7.36%)
Charles Brandes 2,546,580 sh (-9.82%)
» More
Q3 2012

GSK Guru Trades in Q3 2012

Joel Greenblatt 89,990 sh (New)
Jim Simons 2,776,200 sh (+68.15%)
Manning & Napier Advisors, Inc 338,553 sh (+9.72%)
Ken Fisher 11,796,100 sh (+4.62%)
Dodge & Cox 60,242,874 sh (+2.17%)
NWQ Managers 172,157 sh (+0.97%)
John Hussman 19,500 sh (unchged)
Jean-Marie Eveillard 341,601 sh (unchged)
Vanguard Health Care Fund 2,742,381 sh (unchged)
Warren Buffett 1,510,500 sh (unchged)
Murray Stahl 23,673 sh (unchged)
PRIMECAP Management 11,468,755 sh (-0.56%)
Jeff Auxier 70,295 sh (-2.16%)
Tweedy Browne 125,882 sh (-6.85%)
Charles Brandes 2,370,996 sh (-6.89%)
Steven Cohen 43,367 sh (-69.92%)
» More
Q4 2012

GSK Guru Trades in Q4 2012

John Rogers 5,347 sh (New)
John Hussman 523,500 sh (+2584.62%)
Jeff Auxier 112,245 sh (+59.68%)
Tweedy Browne 151,264 sh (+20.16%)
NWQ Managers 205,550 sh (+19.4%)
Dodge & Cox 63,302,825 sh (+5.08%)
Jim Simons 2,858,400 sh (+2.96%)
Manning & Napier Advisors, Inc 344,096 sh (+1.64%)
Jean-Marie Eveillard 341,601 sh (unchged)
Vanguard Health Care Fund 2,742,381 sh (unchged)
Warren Buffett 1,510,500 sh (unchged)
Murray Stahl 23,673 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 10,635,855 sh (-7.26%)
Ken Fisher 10,747,535 sh (-8.89%)
Charles Brandes 2,148,044 sh (-9.4%)
Joel Greenblatt 60,720 sh (-32.53%)
» More
Q1 2013

GSK Guru Trades in Q1 2013

Steven Cohen 11,649 sh (New)
John Rogers 7,024 sh (+31.36%)
Joel Greenblatt 67,332 sh (+10.89%)
Manning & Napier Advisors, Inc 379,591 sh (+10.32%)
NWQ Managers 217,700 sh (+5.91%)
Ken Fisher 11,066,663 sh (+2.97%)
Jeff Auxier 112,870 sh (+0.56%)
Jean-Marie Eveillard 341,601 sh (unchged)
Warren Buffett 1,510,500 sh (unchged)
Tweedy Browne 151,264 sh (unchged)
Dodge & Cox 62,617,647 sh (-1.08%)
Murray Stahl 22,673 sh (-4.22%)
PRIMECAP Management 10,101,855 sh (-5.02%)
Charles Brandes 1,995,632 sh (-7.1%)
Vanguard Health Care Fund 2,180,381 sh (-20.49%)
Jim Simons 1,619,400 sh (-43.35%)
John Hussman 23,500 sh (-95.51%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -95.51%0.57%$43.47 - $46.91 $ 52.9718%23500
Vanguard Health Care Fund 2013-03-31 Reduce -20.49%0.07%$43.47 - $46.91 $ 52.9718%2180381
John Hussman 2012-12-31 Add 2584.62%0.58%$41.9 - $47.45 $ 52.9720%523500
Dodge & Cox 2012-12-31 Add 5.08%0.18%$41.9 - $47.45 $ 52.9720%63302825
Joel Greenblatt 2012-12-31 Reduce -32.53%0.09%$41.9 - $47.45 $ 52.9720%60720
Tweedy Browne 2012-12-31 Add 20.16%0.03%$41.9 - $47.45 $ 52.9720%151264
Joel Greenblatt 2012-09-30 New Buy0.28%$44.25 - $47.23 $ 52.9715%89990
Jean-Marie Eveillard 2012-03-31 New Buy0.06%$43.73 - $46.35 $ 52.9726%322701
Charles Brandes 2011-12-31 Reduce -20.33%0.3%$40.53 - $45.74 $ 52.9720%3035713
David Dreman 2011-09-30 Sold Out 0.0722%$38.84 - $44.91 $ 52.9725%0
Tweedy Browne 2011-09-30 Reduce -20.57%0.05%$38.84 - $44.91 $ 52.9725%148093
John Hussman 2011-09-30 Add 50%$38.84 - $44.91 $ 52.9725%16500
Bruce Berkowitz 2011-06-30 Sold Out 0.05%$38.78 - $43.74 $ 52.9726%0
David Dreman 2011-06-30 Add 43.95%0.02%$38.78 - $43.74 $ 52.9726%87932
Bruce Berkowitz 2011-03-31 New Buy0.05%$36.33 - $39.86 $ 52.9739%190000
David Dreman 2011-03-31 Add 47.39%0.01%$36.33 - $39.86 $ 52.9739%61084
Mario Gabelli 2011-03-31 Sold Out $36.33 - $39.86 $ 52.9739%0
Joel Greenblatt 2011-03-31 Sold Out $36.33 - $39.86 $ 52.9739%0
Joel Greenblatt 2010-12-31 New Buy0.65%$38.28 - $41.86 $ 52.9733%50826
John Hussman 2010-12-31 New Buy0.01%$38.28 - $41.86 $ 52.9733%11000
Mario Gabelli 2010-09-30 Reduce -26.18%$33.78 - $40.47 $ 52.9741%11276
Tweedy Browne 2010-06-30 Reduce -77.28%0.25%$32.34 - $39.57 $ 52.9747%225970
Vanguard Health Care Fund 2010-06-30 Add 20.59%0.08%$32.34 - $39.57 $ 52.9747%2342381
David Dreman 2010-06-30 New Buy0.03%$32.34 - $39.57 $ 52.9747%34560
Dodge & Cox 2010-03-31 Add 5%0.16%$37.03 - $42.97 $ 52.9735%75047144
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about GlaxoSmithKline PLC

The Other Healthcare Stocks of Warren Buffett
December 5, 2012
Warren Buffett - The Other Healthcare Stocks Of Warren Buffett
Large dialysis services provider, DaVita Inc. (DVA) has been receiving magnified attention ever since Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B) first initiated a position in the company in the fourth quarter of 2011, and even more so when the company is seen making increasingly concentrated bullish moves on DaVita over the past several weeks. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.60
GSK's P/E(ttm) is ranked higher than
64% of the 336 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.80 vs. GSK: 20.60 )
GSK' s 10-Year P/E(ttm) Range
Min: 10.17   Max: 40.28
Current: 20.6
10.17
40.28
P/B 16.32
GSK's P/B is ranked lower than
96% of the 420 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. GSK: 16.32 )
GSK' s 10-Year P/B Range
Min: 5.48   Max: 14.77
Current: 16.32
5.48
14.77
P/S 3.28
GSK's P/S is ranked lower than
56% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.81 vs. GSK: 3.28 )
GSK' s 10-Year P/S Range
Min: 1.94   Max: 7.5
Current: 3.28
1.94
7.5
PFCF 28.23
GSK's PFCF is ranked higher than
54% of the 243 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.36 vs. GSK: 28.23 )
GSK' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 28.23
8.21
41.33
EV-to-EBIT 15.78
GSK's EV-to-EBIT is ranked higher than
64% of the 366 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.62 vs. GSK: 15.78 )
GSK' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 239.5
Current: 15.78
7.6
239.5
PEG 17.17
GSK's PEG is ranked lower than
90% of the 165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. GSK: 17.17 )
GSK' s 10-Year PEG Range
Min: 0.28   Max: 257.86
Current: 17.17
0.28
257.86
Shiller P/E 19.28
GSK's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: vs. GSK: 19.28 )
GSK' s 10-Year Shiller P/E Range
Min: 10.59   Max: 20.59
Current: 19.28
10.59
20.59

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 4.43
GSK's Dividend Yield is ranked higher than
97% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.21 vs. GSK: 4.43 )
GSK' s 10-Year Dividend Yield Range
Min: 1.55   Max: 5.69
Current: 4.43
1.55
5.69
Dividend Payout 1.1
GSK's Dividend Payout is ranked lower than
90% of the 193 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. GSK: 1.1 )
GSK' s 10-Year Dividend Payout Range
Min: 0.51   Max: 2.01
Current: 1.1
0.51
2.01
Dividend growth (3y) 5
GSK's Dividend growth (3y) is ranked higher than
90% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GSK: 5 )
GSK' s 10-Year Dividend growth (3y) Range
Min: -9.6   Max: 13
Current: 5
-9.6
13
Yield on cost (5-Year) 6.25
GSK's Yield on cost (5-Year) is ranked higher than
98% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.21 vs. GSK: 6.25 )
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 2.15   Max: 7.91
Current: 6.25
2.15
7.91
Share Buyback Rate 0.6
GSK's Share Buyback Rate is ranked higher than
93% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GSK: 0.6 )
GSK' s 10-Year Share Buyback Rate Range
Min: 2.7   Max: -13.1
Current: 0.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 15.7
GSK's Price/Net Current Asset Value is ranked lower than
54% of the 391 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.80 vs. GSK: 15.7 )
GSK' s 10-Year Price/Net Current Asset Value Range
Min: 9.7   Max: 26.6
Current: 15.7
9.7
26.6
Price/DCF (Projected) 1.8
GSK's Price/DCF (Projected) is ranked higher than
67% of the 160 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. GSK: 1.8 )
GSK' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 1.8
Current: 1.8
1.1
1.8
Price/Median PS Value 1.1
GSK's Price/Median PS Value is ranked higher than
50% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. GSK: 1.1 )
GSK' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.5
Current: 1.1
0.7
2.5
Earnings Yield (Greenblatt) 6.30
GSK's Earnings Yield (Greenblatt) is ranked higher than
71% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. GSK: 6.30 )
GSK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.1
Current: 6.3
0.4
13.1
Forward Rate of Return (Yacktman) 5.16
GSK's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 433 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GSK: 5.16 )
GSK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.6   Max: 56.5
Current: 5.16
-15.6
56.5

Business Description

GlaxoSmithKline PLC incorporated in United Kingdom. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals including HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. It operates in two industry segments: Pharmaceuticals and Consumer Healthcare. The Company's pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. It markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. It produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, it is developing new treatments for cancer. The Company's portfolio comprises three main categories: OTC medicines, Oral healthcare and Nutritional healthcare. OTC medicines- alli is the first licensed weight loss medicine to be available without a prescription, launched in the USA in 2007. Oral healthcare- Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene; Polident, PoliGrip and Corega, the denture care cleansers and adhesives; and Other brands include Odol, Macleans and Dr Best. Nutritional healthcare- Lucozade is a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. The Company has operations in USA, Europe, Asia Pacific, Japan and Canada.
Company Website
Industry: Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT
Traded in other countries:GSK.UK, GLAXF.USA, GS7A.Germany, GS7.Germany
» More Articles for NYSE:GSK

Headlines

Articles On GuruFocus.com
20 Best-Yielding Health Care Stocks - Less Volatile Than the Market Apr 02 2013 
My 4 Favorite Income Stocks with Biggest Earnings Growth Mar 22 2013 
10 Best Dividend Paying Drug Manufacturing Stocks Mar 02 2013 
The Best Yielding Ex-Dividend Stocks for Next Week Feb 17 2013 
Dodge & Cox Explain Why They Are Overweight in Pharmaceuticals Dec 13 2012 
Warren Buffett’s Best-Yielding Dividend Stocks Dec 05 2012 
The Other Healthcare Stocks of Warren Buffett Dec 05 2012 
Yearly Low: GlaxoSmithKline (GSK) Nov 15 2012 
The 20 Biggest Healthcare Dividend Payer Oct 02 2012 
10 Best Yielding Drug Manufacturing Stocks Aug 02 2012 

More From Our Partners
Elan Rejects Royalty Offer Again - Analyst Blog May 24 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial